A two-faced selectivity solution to target SMARCA2 for cancer therapy

Two new studies exploring PROTAC-mediated degradation of SMARCA2 for cancer therapy solve an apparently intractable selectivity challenge with SMARCA4 by utilising the requirement for a productive ternary complex between the protein, PROTAC and ligase complex.

Detalles Bibliográficos
Autores principales: Harling, John D., Tinworth, Christopher P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889305/
https://www.ncbi.nlm.nih.gov/pubmed/36720862
http://dx.doi.org/10.1038/s41467-023-36238-0
_version_ 1784880700643606528
author Harling, John D.
Tinworth, Christopher P.
author_facet Harling, John D.
Tinworth, Christopher P.
author_sort Harling, John D.
collection PubMed
description Two new studies exploring PROTAC-mediated degradation of SMARCA2 for cancer therapy solve an apparently intractable selectivity challenge with SMARCA4 by utilising the requirement for a productive ternary complex between the protein, PROTAC and ligase complex.
format Online
Article
Text
id pubmed-9889305
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98893052023-02-02 A two-faced selectivity solution to target SMARCA2 for cancer therapy Harling, John D. Tinworth, Christopher P. Nat Commun Comment Two new studies exploring PROTAC-mediated degradation of SMARCA2 for cancer therapy solve an apparently intractable selectivity challenge with SMARCA4 by utilising the requirement for a productive ternary complex between the protein, PROTAC and ligase complex. Nature Publishing Group UK 2023-01-31 /pmc/articles/PMC9889305/ /pubmed/36720862 http://dx.doi.org/10.1038/s41467-023-36238-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Comment
Harling, John D.
Tinworth, Christopher P.
A two-faced selectivity solution to target SMARCA2 for cancer therapy
title A two-faced selectivity solution to target SMARCA2 for cancer therapy
title_full A two-faced selectivity solution to target SMARCA2 for cancer therapy
title_fullStr A two-faced selectivity solution to target SMARCA2 for cancer therapy
title_full_unstemmed A two-faced selectivity solution to target SMARCA2 for cancer therapy
title_short A two-faced selectivity solution to target SMARCA2 for cancer therapy
title_sort two-faced selectivity solution to target smarca2 for cancer therapy
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889305/
https://www.ncbi.nlm.nih.gov/pubmed/36720862
http://dx.doi.org/10.1038/s41467-023-36238-0
work_keys_str_mv AT harlingjohnd atwofacedselectivitysolutiontotargetsmarca2forcancertherapy
AT tinworthchristopherp atwofacedselectivitysolutiontotargetsmarca2forcancertherapy
AT harlingjohnd twofacedselectivitysolutiontotargetsmarca2forcancertherapy
AT tinworthchristopherp twofacedselectivitysolutiontotargetsmarca2forcancertherapy

Ejemplares similares